Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,650 Million (Small Cap)
17.00
NA
2.12%
-0.76
5.93%
1.00
Revenue and Profits:
Net Sales:
69 Million
(Quarterly Results - Jun 2025)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
6.38%
0%
6.38%
1 Year
-7.08%
0%
-7.08%
2 Years
-25.14%
0%
-25.14%
3 Years
-2.59%
0%
-2.59%
4 Years
-26.01%
0%
-26.01%
5 Years
-50.15%
0%
-50.15%
Beijing Succeeder Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.94%
EBIT Growth (5y)
5.08%
EBIT to Interest (avg)
90.16
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.17
Tax Ratio
13.21%
Dividend Payout Ratio
30.84%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
46.66%
ROE (avg)
6.79%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
1.00
EV to EBIT
4.49
EV to EBITDA
3.92
EV to Capital Employed
1.00
EV to Sales
1.39
PEG Ratio
NA
Dividend Yield
2.12%
ROCE (Latest)
22.40%
ROE (Latest)
5.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
69.10
82.40
-16.14%
Operating Profit (PBDIT) excl Other Income
25.80
32.30
-20.12%
Interest
0.00
0.00
Exceptional Items
0.50
0.30
66.67%
Consolidate Net Profit
24.80
32.30
-23.22%
Operating Profit Margin (Excl OI)
327.40%
358.20%
-3.08%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -16.14% vs 11.35% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -23.22% vs -3.87% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
301.20
272.70
10.45%
Operating Profit (PBDIT) excl Other Income
113.20
105.20
7.60%
Interest
0.10
0.10
Exceptional Items
0.20
0.00
Consolidate Net Profit
112.90
116.90
-3.42%
Operating Profit Margin (Excl OI)
336.60%
367.70%
-3.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.45% vs 20.56% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -3.42% vs 12.30% in Dec 2023
About Beijing Succeeder Technology, Inc. 
Beijing Succeeder Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






